FMOD has been recognized as a novel tumor-associated antigen in lymphoma, leiomyoma, and leukemia [43], and FMOD has been detected in various clinical malignancies, such as breast, prostate, and lung carcinomas [44,45,46]. The gene discussed is FMOD; the disease is lung carcinoma.